Metabolic syndrome is a combination of pathological conditions, including insulin resistance, arterial hypertension, hyperlipidemia, and abdominal obesity, which significantly affect various body systems. One of the important aspects of metabolic syndrome is its impact on eye health, especially on the development of inflammatory diseases such as conjunctivitis. Conjunctivitis against the background of metabolic syndrome can have various clinical manifestations, including redness, itching, tearing, and eye swelling. The pathogenesis of these diseases includes both the direct effect of metabolic disorders and the secondary weakening of immune defense. Endocrine and metabolic disorders contribute to changes in the structure of tear fluid, which increases susceptibility to inflammation and infections.

A comprehensive approach to treating conjunctivitis against the background of metabolic syndrome includes both systemic and local therapeutic methods. The most important areas of treatment are the correction of metabolic disorders using drugs aimed at reducing blood sugar levels, improving lipid metabolism, and normalizing blood pressure. Local treatment of conjunctivitis includes the appointment of anti-inflammatory and antiseptic medications, as well as the use of medications to improve the condition of the tear film. Thus, effective treatment of conjunctivitis in patients with metabolic syndrome requires an individual approach, which includes both the correction of the underlying disease and the use of specific therapy to reduce inflammation and prevent complications.

Conjunctivitis, metabolic syndrome, complex treatment, influence of metabolic syndrome, diabetic retinopathy, insulin resistance

K.Lekhanont et al. Effect of topical olopatadine and epinastine in the botulinum toxin B-induced mouse model of dry eye. // J Ocul Pharmacol Ther. 2007 Feb; 23(1): 83-8. D

Pan Q. et al. Autologous serum eye drops for dry eye //Cochrane Database of Systematic Reviews. – 2017. – №. 2.

Bielory L., Lien K. W., Bigelsen S. Efficacy and tolerability of newer antihistamines in the treatment of allergic conjunctivitis //Drugs. – 2005. – Т. 65. – №. 2. – С. 215-228.

Azari A. A., Barney N. P. Conjunctivitis: a systematic review of diagnosis and treatment //Jama. – 2013. – Т. 310. – №. 16. – С. 1721-1730.

Owen CG, Shah A, Henshaw K, et al. Topical treatments for seasonal allergic conjunctivitis: systematic review and meta-analysis of efficacy and effectiveness. //Br J Gen Pract. – 2004. – v.54(503). – P.451-456.

Hwang D. G. et al. A phase III, placebo controlled clinical trial of 0.5% levofloxacin ophthalmic solution for the treatment of bacterial conjunctivitis //British journal of ophthalmology. – 2003. – Т. 87. – №. 8. – С. 1004-1009.

Boboeva Ranо Rakhimovna. Improvement of Methods of Treatment of Retinal Angiopathies of Various Etiologies: //Journal of Natural and Medical Education Year 2024;3(2).

Бобоева Раъно Рахимовна. Совершенствование методов лечения ангиопатий сетчатки различной этиологии. //Journal of science in medicine and life. 2024; с. 61-65.

Бобоева Раъно Рахимовна. Комплексный подход к течению и лечению конъюнктивитов на фоне метаболического синдрома .// world scientific research journal volume-38_issue-1_april-2025 ,84-90ст